A Study Exploring Efficacy of Pegloticase in Subjects With Asymptomatic Hyperuricemia

PHASE1CompletedINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

April 11, 2022

Primary Completion Date

January 9, 2023

Study Completion Date

January 9, 2023

Conditions
Asymptomatic Hyperuricemia
Interventions
DRUG

SIBP-R002

SIBP-R002: injection; strength: 1, 2, 4, 8 or 12 mg; dose escalation and the first group is 1mg (intravenous infusion, 5 groups, the first group consisted of four people, and the other groups consisted of eight).

DRUG

Dexamethasone or Methyl prednisolone

Intravenous infusion, 5mg or 1\~2mg/kg. These were administered within 30 minutes prior to infusion of the experimental drug.

DRUG

Diphenhydramine

10mg, intramuscular injection.These were administered within 30 minutes prior to infusion of the experimental drug.

DRUG

Placebo

The same volume of placebo as SIBP-R002: injection; strength: the same volume of placebo as SIBP-R002 of 1, 2, 4, 8 or 12 mg (intravenous infusion, 5 groups, the first group consisted of one people, and the other groups consisted of two). The rule and dose of placebo were the same as SIBP-R002.

Trial Locations (1)

Unknown

The first affiliated hospital of Bengbu medical college, Bengbu

All Listed Sponsors
collaborator

The First Affiliated Hospital of Bengbu Medical University

OTHER

lead

Shanghai Institute Of Biological Products

INDUSTRY